Genmab A/S (NASDAQ:GMAB) Sets New 1-Year Low – Time to Sell?

Genmab A/S (NASDAQ:GMAB)’s stock price reached a new 52-week low during trading on Wednesday . The company traded as low as $21.86 and last traded at $21.86, with a volume of 979956 shares trading hands. The stock had previously closed at $22.47.

Analyst Ratings Changes

GMAB has been the topic of several analyst reports. Redburn Atlantic started coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They issued a “buy” rating on the stock. BMO Capital Markets reaffirmed an “outperform” rating and set a $48.00 target price (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Morgan Stanley reissued an “equal weight” rating and issued a $31.00 price target on shares of Genmab A/S in a report on Wednesday, September 11th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Genmab A/S in a research note on Tuesday, August 20th. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a report on Wednesday, October 16th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $45.20.

Genmab A/S Price Performance

The firm’s fifty day simple moving average is $24.08 and its 200 day simple moving average is $26.28. The company has a market capitalization of $14.02 billion, a PE ratio of 20.56, a price-to-earnings-growth ratio of 0.68 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). The company had revenue of $816.10 million during the quarter, compared to analysts’ expectations of $838.20 million. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. During the same quarter in the previous year, the company earned $0.47 EPS. On average, equities research analysts anticipate that Genmab A/S will post 1.28 EPS for the current fiscal year.

Institutional Trading of Genmab A/S

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GMAB. Russell Investments Group Ltd. increased its stake in shares of Genmab A/S by 137.7% in the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock valued at $28,000 after purchasing an additional 544 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new position in shares of Genmab A/S during the 1st quarter valued at approximately $43,000. Blue Trust Inc. grew its stake in Genmab A/S by 892.0% in the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock valued at $108,000 after acquiring an additional 3,880 shares during the period. Headlands Technologies LLC grew its stake in Genmab A/S by 1,702.8% in the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock valued at $129,000 after acquiring an additional 4,853 shares during the period. Finally, Benjamin F. Edwards & Company Inc. increased its holdings in Genmab A/S by 7.1% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock worth $182,000 after acquiring an additional 478 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.